» Articles » PMID: 34010338

Public Support for Harm Reduction: A Population Survey of Canadian Adults

Abstract

We described public views toward harm reduction among Canadian adults and tested a social exposure model predicting support for these contentious services, drawing on theories in the morality policy, intergroup relations, addiction, and media communication literatures. A quota sample of 4645 adults (18+ years), randomly drawn from an online research panel and stratified to match age and sex distributions of adults within and across Canadian provinces, was recruited in June 2018. Participants completed survey items assessing support for harm reduction for people who use drugs (PWUD) and for seven harm reduction interventions. Additional items assessed exposure to media coverage on harm reduction, and scales assessing stigma toward PWUD (α = .72), personal familiarity with PWUD (α = .84), and disease model beliefs about addiction (α = .79). Most (64%) Canadians supported harm reduction (provincial estimates = 60% - 73%). Five of seven interventions received majority support, including: outreach (79%), naloxone (72%), drug checking (70%), needle distribution (60%) and supervised drug consumption (55%). Low-threshold opioid agonist treatment and safe inhalation interventions received less support (49% and 44%). Our social exposure model, adjusted for respondent sex, household income, political views, and education, exhibited good fit and accounted for 17% of variance in public support for harm reduction. Personal familiarity with PWUD and disease model beliefs about addiction were directly associated with support (βs = .07 and -0.10, respectively), and indirectly influenced public support via stigmatized attitudes toward PWUD (βs = 0.01 and -0.01, respectively). Strategies to increase support for harm reduction could problematize certain disease model beliefs (e.g., "There are only two possibilities for an alcoholic or drug addict-permanent abstinence or death") and creating opportunities to reduce social distance between PWUD, the public, and policy makers.

Citing Articles

Effects of the Communities that Heal (CTH) intervention on perceived opioid-related community stigma in the HEALing Communities Study: results of a multi-site, community-level, cluster-randomized trial.

Davis A, Knudsen H, Walker D, Chassler D, Lunze K, Westgate P Lancet Reg Health Am. 2024; 32:100710.

PMID: 38510790 PMC: 10950860. DOI: 10.1016/j.lana.2024.100710.


Harm reduction strategies in acute care for people who use alcohol and/or drugs: A scoping review.

Crowther D, Curran J, Somerville M, Sinclair D, Wozney L, MacPhee S PLoS One. 2023; 18(12):e0294804.

PMID: 38100469 PMC: 10723714. DOI: 10.1371/journal.pone.0294804.


Canadian newspaper coverage on harm reduction featuring bereaved mothers: A mixed methods analysis.

Morris H, Wild T, Giovannoni M, Haines-Saah R, Koziel J, Schulz P PLoS One. 2023; 18(11):e0294608.

PMID: 38011175 PMC: 10681218. DOI: 10.1371/journal.pone.0294608.


"It's starting to weigh on me": Exploring the Experiences and Support Needs of Harm Reduction Staff in Connecticut using the Social-Ecological Model.

Hill K, Dunham K, Grau L, Heimer R Harm Reduct J. 2023; 20(1):168.

PMID: 37964261 PMC: 10644636. DOI: 10.1186/s12954-023-00898-4.


Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the HEALing Communities Study.

Davis A, Stringer K, Drainoni M, Oser C, Knudsen H, Aldrich A Int J Drug Policy. 2023; 122:104241.

PMID: 37890391 PMC: 10841835. DOI: 10.1016/j.drugpo.2023.104241.


References
1.
Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh D . The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. J Urban Health. 2008; 85(6):812-25. PMC: 2587648. DOI: 10.1007/s11524-008-9312-9. View

2.
Tempalski B, McQuie H . Drugscapes and the role of place and space in injection drug use-related HIV risk environments. Int J Drug Policy. 2008; 20(1):4-13. PMC: 3615636. DOI: 10.1016/j.drugpo.2008.02.002. View

3.
Pettigrew T, Tropp L . A meta-analytic test of intergroup contact theory. J Pers Soc Psychol. 2006; 90(5):751-83. DOI: 10.1037/0022-3514.90.5.751. View

4.
van Boekel L, Brouwers E, van Weeghel J, Garretsen H . Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013; 131(1-2):23-35. DOI: 10.1016/j.drugalcdep.2013.02.018. View

5.
Vederhus J, Clausen T, Humphreys K . Assessing understandings of substance use disorders among Norwegian treatment professionals, patients and the general public. BMC Health Serv Res. 2016; 16:52. PMC: 4752790. DOI: 10.1186/s12913-016-1306-9. View